RxDoctor Payments Data

Pawel Zelenski, MD

Internal Medicine · Saint Cloud, FLNPI 1609846633

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by GSK at 24.6% of the total. Reporting peaked in 2023 at $142 and has fallen 52.6% since, to $68 in 2025. That places this record below the midpoint for internal medicine clinicians in FL, where the typical reported total is $316.

$321in general payments, 2019–2025

Across 16 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$79
  • Exact Sciences$48
  • Sanofi-aventis U.S. LLC$38
  • Amgen$37
  • Novo Nordisk$34
  • Abbott$25
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$321100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$321 in reported general payments places this provider in the 50th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida →

Medicare billing

Part B allowed, 2024
$131,510
Medicare patients
243
Services billed
1,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$108,761
OzempicSemaglutide45$56,595
JardianceEmpagliflozin45$49,239
JanuviaSitagliptin Phosphate32$38,641
JanumetSitagliptin Phos/Metformin Hcl15$17,745
XareltoRivaroxaban18$14,824
Repatha SureclickEvolocumab21$12,303
FarxigaDapagliflozin Propanediol11$7,878
Breo ElliptaFluticasone/Vilanterol15$5,826
Atorvastatin Calcium597$5,261
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$5,218
Levothyroxine Sodium332$3,653
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$3,589
Rosuvastatin Calcium193$3,426
SymbicortBudesonide/Formoterol Fumarate13$3,249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$34$56,59545 claims
GSKBreo Ellipta$79$5,82615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Saint Cloud

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →